Zydus Lifesciences (Cadila Healthcare) has rolled out the molecule Sitagliptin in India under the Sitaglyn and Siglyn brand names for the treatment of Type 2 diabetes in the country.

Sitaglyn and Siglyn are intended to be delivered as an oral solution.

According to Zydus Lifesciences, Sitaglyn drug is said to offer best-in-class achievement of the goals of Hemoglobin A1C (HbA1c) with a proven safety profile.

Dr. Sharvil Patel — Zydus Lifesciences Managing Director said: “The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes better by making it more affordable.

“Our high quality product will expand the reach of the molecule to patients in India, supported by our wide distribution network. The drug will help patients achieve their HbA1C goals reducing the disease burden and providing better patient-care and quality of life.”

The diabetes brands of Zydus Lifesciences include Lipaglyn, Vinglyn, Dapaglyn, and Tenglyn.

  Cadila Healthcare, Diabetes, Dr. Sharvil Patel, India, Siglyn, Sitagliptin, Sitaglyn, Type 2 Diabetes, Zydus Lifesciences